The collaboration, announced in December 2006, calls for Neuroptix to provide Merck with access to its laser eye scanning technologies, which in preclinical studies has detected Alzheimer’s-related amyloid protein aggregates in the lens of the eye. The quantitative technique has the potential for early detection and monitoring of Alzheimer’s Disease progression.
“We are looking forward to continued success as we advance the development of our eye test for early detection of Alzheimer’s Disease, for use in clinical diagnostic settings and for monitoring clinical trials of new Alzheimer’s drugs in the pipeline,” said Paul Hartung, president and CEO of Neuroptix.